Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 9/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HRH1 | P35367 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | HTR1E | P28566 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24671662 | 1.00 | NR1H2 (0.48) | NR1H2ESR2TMEM97SIGMAR1PRMT5 | |
| SCHEMBL30851452 | 0.97 | ESR2 (0.52) | NR1H2ESR2TMEM97SIGMAR1PRMT5 | |
| SCHEMBL24671063 | 0.97 | ESR2 (0.52) | NR1H2ESR2TMEM97SIGMAR1PRMT5 | |
| SCHEMBL19585783 | 0.93 | PRMT5 (0.42) | ESR2TMEM97SIGMAR1PRMT5GPR119 | |
| SCHEMBL30768963 | 0.89 | PRMT5 (0.44) | TMEM97SIGMAR1PRMT5GPR119HRH2 | |
| SCHEMBL29207882 | 0.88 | TMEM97 (0.43) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL30066338 | 0.86 | TMEM97 (0.47) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL30768875 | 0.85 | PRMT5 (0.43) | PRMT5GPR119MAPK1TLR9TLR7 | |
| SCHEMBL30768343 | 0.85 | PRMT5 (0.43) | PRMT5GPR119MAPK1TLR9TLR7 | |
| SCHEMBL30768838 | 0.85 | PRMT5 (0.43) | PRMT5GPR119MAPK1TLR9TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | NR1H2 1820/4885ESR2 1491/4885TMEM97 4041/4885 |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | NR1H2 21/4885ESR2 3/4885TMEM97 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.